SAGE PRO

Home / Research / Advanced Enzyme Technologies Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Advanced Enzyme Technologies Limited — Q2 FY27 Results Analysis

Revenue grew in Q2

Published · Quarter Q2 FY27 · ADVENZYMES

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Consolidated revenue

Q2 FY26₹1,845 million
Q2 FY27₹2,145 million

https://nsearchives.nseindia.com/corporate/AETL_31102026153231_IntimationIP.pdf

CHART 2

Consolidated EBITDA

Q2 FY26₹601 million
Q2 FY27₹721 million

https://nsearchives.nseindia.com/corporate/AETL_31102026153231_IntimationIP.pdf

CHART 3

Consolidated PAT

Q2 FY26₹447 million
Q2 FY27₹512 million

https://nsearchives.nseindia.com/corporate/AETL_31102026153231_IntimationIP.pdf

CHART 4

Sequential margin recovery

Q1 FY2728%
Q2 FY2734%

https://nsearchives.nseindia.com/corporate/AETL_31102026153231_IntimationIP.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Revenue grew in Q2

Q2 FY27 ₹2,145m versus ₹1,845m year earlier

Watch: Compare Q3 with both Q2 and H1

RESEARCH INSIGHT

Operating profit accelerated

Q2 EBITDA ₹721m versus ₹601m year earlier

Watch: Monitor sustainability of 34% margin

RESEARCH INSIGHT

PAT rose more slowly than EBITDA

PAT before minority ₹512m versus ₹447m

Watch: Reconcile minority interest in future reports

RESEARCH INSIGHT

Margin rebounded from Q1

EBITDA margin about 28% to 34%

Watch: Watch input costs and mix

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

Advanced Enzyme Technologies Limited (NSE: ADVENZYMES) | Q2 FY2027 | Quarter ended 30 September 2026 | Consolidated financial basis unless otherwise stated

Decision: WATCH — improving quarter, but the quality of the next two quarters matters more than one strong comparison. Advanced Enzyme reported consolidated Q2 revenue of ₹2,145 million, up 16% from ₹1,845 million a year earlier. EBITDA increased to ₹721 million from ₹601 million and profit after tax to ₹512 million from ₹447 million. The company has delivered both sales growth and a higher EBITDA margin, although its half-year results show that the acceleration is concentrated in Q2 rather than uniformly spread across the first six months. S1 S2

At a glance: Q2 revenue +16% year on year; EBITDA +20%; PAT +14%; EBITDA margin approximately 34% versus 33% last year and 28% in Q1 FY27. H1 revenue grew 10%, EBITDA 7%, and PAT 5%. These comparisons are consolidated and the presentation labels PAT before minority interest. Investors should not interchange that figure with profit attributable to shareholders without a reconciliation. S2

Consolidated measureQ2 FY26Q1 FY27Q2 FY27Interpretation
Revenue (₹ million)1,8451,9172,145Growth accelerated sequentially
EBITDA (₹ million)601529721Profitability recovered more quickly than revenue
PAT before minority (₹ million)447386512Up 14% year on year and 33% sequentially
EBITDA marginabout 33%about 28%about 34%Improved operating leverage

These figures come from the October 2026 earnings presentation and were discussed by management on 3 November 2026. The presentation describes certain Ind AS adjustments for commission, discount and provisions for sales returns. S1 S2

1. Investment thesis and valuation conditions

The investment question is whether a specialist enzyme manufacturer can convert its broad end-market exposure into durable revenue growth while maintaining margins near the level delivered in Q2. The quarter offers encouraging evidence: revenue increased, EBITDA grew faster than revenue and several business segments contributed. The comparison is especially notable because management referred to elevated power, fuel and raw-material costs. The reported result suggests that operating efficiency, mix or scale helped absorb those pressures during the quarter. S1

However, Q2 alone does not prove a permanently higher earnings base. The H1 revenue increase of 10% was accompanied by only 7% EBITDA growth and 5% PAT growth. That distinction matters: a valuation based on Q2's strong exit rate could be too optimistic if earlier-quarter weakness returns. Investors should therefore compare future growth against both Q2 and the H1 run rate, rather than extrapolating one quarter mechanically. S2

No current market price, enterprise value, share count or verified trailing earnings multiple is included in the two accepted source documents used for this briefing. A precise target price or claimed upside would therefore be unsupported. The valuation condition is qualitative: a premium becomes easier to defend if recurring segment growth and sustainable margins are demonstrated across several reporting periods; it becomes harder to defend if the Q2 improvement reverses or cash conversion disappoints. S1 S2

The company also completed an open-market share buyback involving 2.41 million shares at an average ₹289.09 per share, according to management. A buyback can change per-share comparisons and capital allocation, but it is not, by itself, evidence that the stock is undervalued. Assess future per-share earnings together with operating results, not as a substitute for them. S1

2. Q2 and first-half financial performance

Consolidated Q2 revenue increased by ₹300 million year on year, from ₹1,845 million to ₹2,145 million. EBITDA rose by approximately ₹120 million, from ₹601 million to ₹721 million. Profit before tax increased from about ₹595 million to ₹688 million, while PAT before minority interest rose from ₹447 million to ₹512 million. These are the management-presented comparisons, with rounding in the verbal transcript. S1 S2

Sequentially, revenue advanced from ₹1,917 million in Q1 FY27 to ₹2,145 million in Q2, a gain of about 12%. EBITDA moved from ₹529 million to ₹721 million, roughly 36% higher, and PAT from ₹386 million to ₹512 million, approximately 33% higher. The much faster sequential rise in profit than sales indicates meaningful operating leverage in Q2, but the next result will show whether it was repeatable. S2

The first-half comparison is more measured. H1 FY27 revenue was ₹4,062 million versus ₹3,704 million in H1 FY26, a 10% increase. EBITDA was ₹1,250 million versus ₹1,165 million, a 7% increase. PAT was ₹897 million versus ₹852 million, a 5% increase. H1 EBITDA margin was about 31% in both periods, and the H1 PAT margin was approximately 22%. The half-year results argue against treating Q2's 34% EBITDA margin as the only relevant profitability benchmark. S2

H1 consolidated measureH1 FY26H1 FY27Growth
Revenue (₹ million)3,7044,062about 10%
EBITDA (₹ million)1,1651,250about 7%
PAT before minority (₹ million)852897about 5%

An important distinction is that EBITDA and PAT are not cash flow. They do not establish how much cash was collected, how inventories changed or whether investment expenditure rose. Any assessment of cash generation needs the relevant balance-sheet and cash-flow disclosures rather than assuming that accounting profit equals cash available for distribution. S2

3. Products, segments and business mix

Advanced Enzyme's reported segment mix includes Human Healthcare, Animal Healthcare, Bio-Processing and Specialized Manufacturing. Management reported Q2 Human Healthcare revenue of ₹1,285 million, up 6% year on year and 11% sequentially. This is the largest reported category, contributing around 60% of total quarterly sales. The discussion linked its growth to improved Pharma/API, biocatalysis and nutrition business. Its H1 growth was broadly flat, however, so this large segment is a crucial test of sustained recovery. S1

Animal Healthcare generated ₹265 million of Q2 revenue, up 37% year on year and 5% sequentially, with H1 growth of 14%. Bio-Processing generated ₹365 million, up 43% year on year and 19% sequentially; its H1 growth was 37%. Specialized Manufacturing reported ₹231 million, up 25% year on year and 15% sequentially, with H1 growth of 32%. The segment amounts are management's rounded presentation figures and may not sum exactly to the reported consolidated total. S1

Q2 FY27 segmentRevenue (₹ million)Year-on-year growth
Human Healthcare1,2856%
Animal Healthcare26537%
Bio-Processing36543%
Specialized Manufacturing23125%

The smaller categories grew much faster than Human Healthcare in Q2. This is positive for diversification, but it also raises a question about mix and profitability: growth in a smaller segment does not automatically mean equivalent growth in group earnings. Investors should track whether the faster-growing businesses maintain their momentum without requiring disproportionate spending or diluting consolidated margins. S1

The presentation provides a useful segment comparison, while the call offers management's interpretation of why growth occurred. Neither should be mistaken for a guarantee of future orders or segment profitability. A particularly important indicator is whether Human Healthcare can move beyond its relatively subdued first-half performance while the other businesses continue expanding. S1 S2

4. Management commentary and execution

Management described Q2 as a broad-based improvement and expressed confidence in progressive momentum through the rest of FY27. It also advised shareholders to evaluate the business over an annual horizon rather than judge it from a single quarter. That caution is relevant because the difference between Q2 and H1 growth rates is material. The best test of management's confidence is future reported revenue, margins and segment delivery, not the optimism of the call itself. S1

The call highlighted operational efficiency despite pressure from energy and raw-material costs. Reported EBITDA margin expanded to about 34% in Q2, compared with 28% in Q1 FY27. Management therefore has an observable operational achievement to defend. A subsequent fall in margin would not automatically invalidate the strategy, but the reason—mix, input costs, pricing or one-time effects—would need to be explained. S1

Subsidiary performance was mixed. Management reported JC Biotech Q2 revenue of around ₹200 million compared with ₹186 million a year earlier, but EBITDA declined from ₹37 million to ₹29 million. Evoxx reported around ₹75 million revenue and a quarterly loss, while SciTech reported ₹234 million revenue and ₹61 million EBITDA versus ₹185 million revenue and ₹33 million EBITDA in the year-earlier quarter. These differences show why a consolidated margin improvement should be tested against individual business economics. S1

Management's completed buyback is a concrete capital-allocation action. Future assessment should distinguish shareholder distributions from investment needed to maintain technology, capacity and customer relationships. A company can generate attractive operating profit yet still require significant reinvestment; neither the buyback nor the quarterly EBITDA margin alone resolves that trade-off. S1

5. Cash, debt and investment discipline

The accepted transcript and presentation support discussion of reported earnings and the completed share buyback, but they do not establish a complete, reconciled Q2 cash-flow bridge within the figures used here. Accordingly, this briefing does not claim a specific net-cash position, free-cash-flow yield, debt reduction or capital expenditure payback. Those measures should be added only when supported by the corresponding financial statements. S1 S2

The buyback of 2.41 million shares at an average ₹289.09 implies a transaction value of roughly ₹697 million before any related costs, calculated from management's disclosed figures. This is a simple multiplication, not a claim about total program cost or closing cash. Investors should compare this capital return with cash generated by operations and the funding needs of the enzyme businesses. S1

There are three practical financial questions for the next reporting cycle. First, does the stronger Q2 operating profit translate into operating cash flow? Second, do working-capital requirements grow faster than sales as the smaller segments expand? Third, are investments and acquisitions, if any, producing measurable returns rather than simply adding revenue? None of these questions is answered by EBITDA growth alone. S2

The operating margin improvement is encouraging because it creates potential financial flexibility. Yet a high-margin quarter should not be treated as unrestricted cash. Receivables, inventories, taxes, capital expenditure and subsidiary losses can materially change cash conversion. This distinction is particularly important when comparing the group with other specialty-ingredient or biotechnology companies that have different investment cycles. S1

6. Bull, base and bear conditions

Bull case: Human Healthcare returns to stronger growth, Bio-Processing and Animal Healthcare sustain their recent gains, and Specialized Manufacturing continues to scale. Consolidated revenue then grows consistently while EBITDA margin remains near the improved Q2 level. The investment thesis strengthens if that operating performance also produces dependable cash conversion. This is a conditional scenario, not a management forecast or a price target. S1 S2

Base case: Revenue continues to grow, but at a pace closer to H1's 10% rather than assuming the 16% Q2 rate persists. Margins fluctuate with business mix and input costs, leaving the full-year outcome less impressive than the latest quarter alone suggests. The company remains worth monitoring, but a valuation premium would require better evidence of sustained returns and cash generation. S2

Bear case: The stronger Q2 comparison proves temporary. Human Healthcare remains sluggish, subsidiary losses or weaker economics offset gains in faster-growing businesses, and energy or raw-material costs reduce operating margin. A decline in profitability alongside higher working-capital needs would weaken the earnings quality and could justify a lower valuation multiple. S1

The main risks are therefore not abstract. They are identifiable in the source record: uneven segment growth, subsidiary profit divergence, exposure to operating costs, and the difference between quarterly acceleration and half-year trends. Investors should also monitor whether the disclosed PAT before minority interest translates into the earnings measure attributable to equity shareholders. S1 S2

7. Investor action plan and what to watch

Current action: WATCH, not an automatic buy. The operating quarter is strong enough to merit follow-up, but a disciplined decision needs evidence that the improvement lasts. Before assigning a valuation or position size, obtain a current market price, verified share count, relevant earnings basis, balance sheet and cash-flow statement. None is inferred from the two accepted narrative documents. S1 S2

At the next quarterly update, compare revenue with Q2's ₹2,145 million and H1's ₹4,062 million; compare EBITDA margin with both the Q2 level near 34% and H1 level near 31%. A result closer to the H1 margin is not automatically a failure, but it would make Q2's peak less suitable as a valuation anchor. Check whether PAT grows at least broadly in line with revenue after considering minority interests. S2

Track Human Healthcare separately because it represents the majority of sales and had much slower H1 growth than the smaller categories. Watch whether Bio-Processing's 43% Q2 growth and Animal Healthcare's 37% Q2 growth continue from a higher base. Also monitor JC Biotech profitability, Evoxx losses and SciTech's margin progress, rather than looking only at group totals. S1

A stronger investment case would require at least two further reporting periods showing consistent segment demand, sustainable operating profitability and cash conversion. A weaker case would emerge if consolidated margin fell sharply without an identifiable temporary cause, or if rapid revenue growth required disproportionate working capital and capital spending. The triggers are deliberately tied to reported operating evidence rather than a fabricated share-price forecast. S1 S2

Sources: S1 — Advanced Enzyme Technologies, Q2 FY27 earnings call transcript, call dated 3 November 2026 and exchange filing dated 5 November 2026. S2 — Advanced Enzyme Technologies, Q2 FY27/H1 FY27 earnings presentation filed 31 October 2026. Figures are in ₹ million unless stated otherwise.

Additional company evidence

CHART 5

Half-year revenue

H1 FY26₹3,704 million
H1 FY27₹4,062 million

https://nsearchives.nseindia.com/corporate/AETL_31102026153231_IntimationIP.pdf

CHART 6

Half-year EBITDA

H1 FY26₹1,165 million
H1 FY27₹1,250 million

https://nsearchives.nseindia.com/corporate/AETL_31102026153231_IntimationIP.pdf

CHART 7

Segment revenue mix

Human Healthcare₹1,285 million
Animal Healthcare₹265 million
Bio-Processing₹365 million
Specialized Manufacturing₹231 million

https://nsearchives.nseindia.com/corporate/AETL_31102026153231_IntimationIP.pdf

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure
  2. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.